Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma

Bone Marrow Transplantation volume 34, pages 485–490 (2004)Cite this article

Summary:

Given the survival advantage, high-dose therapy (HDT) remains the standard of care for patients with multiple myeloma eligible for the procedure. For those undergoing HDT, initial therapy aimed at reducing tumor burden is given prior to stem cell harvest. Various regimens, mostly variations of VAD (vincristine, doxorubicin, dexamethasone), are used for induction therapy. We retrospectively evaluated if single agent dexamethasone would be an effective induction therapy, given that it is the most active drug in these combinations. A total of 35 patients who received induction therapy with dexamethasone alone were compared to a similar group of 72 patients who received VAD as the initial therapy. We found a 63% response rate with dexamethasone compared to 74% with VAD (P=0.25). Including minimal responses, the overall response rate for Dex and VAD was 74 and 86%, respectively (P=0.13). The overall and complete response rates to transplant, respectively, were 97 and 26% for the dexamethasone group and 100 and 39% for the VAD group; P=0.33 and 0.18. No significant differences were observed in the progression-free and overall survival at 1 year post transplant. Single agent dexamethasone appears to be an effective alternative to VAD for induction therapy prior to HDT in myeloma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26.

    Article  Google Scholar 

  2. Kyle RA . Long-term survival in multiple myeloma. N Engl J Med 1983; 308: 314–316.

    Article  CAS  Google Scholar 

  3. Bataille R, Harousseau JL . Multiple myeloma. N Engl J Med 1997; 336: 1657–1664.

    Article  CAS  Google Scholar 

  4. Alexanian R, Bonnet J, Gehan E et al. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382–389.

    Article  CAS  Google Scholar 

  5. McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822–824.

    Article  CAS  Google Scholar 

  6. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301.

    CAS  Google Scholar 

  7. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  8. Blade J, Esteve J, Rives S et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845–849.

    Article  CAS  Google Scholar 

  9. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  Google Scholar 

  10. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    CAS  Google Scholar 

  11. Attal M, Harousseau J, Facon T et al. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the ‘Intergroupe Francophone du Myelome’ (IFM 94). Blood 2002; 100 (Abstr. #7).

  12. Knudsen LM, Rasmussen T, Jensen L, Johnsen HE . Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment. Med Oncol 1999; 16: 245–254.

    Article  CAS  Google Scholar 

  13. Barlogie B, Smith L, Alexanian R . Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353–1356.

    Article  CAS  Google Scholar 

  14. Alexanian R, Dimopoulos MA, Delasalle KB et al. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 1995; 13 (Suppl 2): 118–121.

    Google Scholar 

  15. Kumar S, Lacy MQ, Dispenzieri A et al. Autologous peripheral blood stem cell transplantation for primary refractory multiple myeloma. Blood 2002; 100: 432a.

    Google Scholar 

  16. Greipp PR, Lust JA, O'Fallon WM et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387.

    CAS  Google Scholar 

  17. Samson D, Gaminara E, Newland A et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 2: 882–885.

    Article  CAS  Google Scholar 

  18. Segeren CM, Sonneveld P, van der Holt B et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999; 105: 127–130.

    Article  CAS  Google Scholar 

  19. Alexanian R, Barlogie B, Dixon D . High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8–11.

    Article  CAS  Google Scholar 

  20. Friedenberg WR, Kyle RA, Knospe WH et al. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol 1991; 36: 171–175.

    Article  CAS  Google Scholar 

  21. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B . Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887–890.

    CAS  Google Scholar 

  22. Egerer G, Hegenbart U, Salwender H et al. Outpatient treatment of multiple myeloma with a combination of vincristine, adriamycin and dexamethasone. Support Care Cancer 2001; 9: 380–385.

    Article  CAS  Google Scholar 

  23. Jackson DV, Case LD, Pope EK et al. Single agent vincristine by infusion in refractory multiple myeloma. J Clin Oncol 1985; 3: 1508–1512.

    Article  CAS  Google Scholar 

  24. Alberts DS, Salmon SE . Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. Cancer Chemother Rep 1975; 59: 345–350.

    CAS  PubMed  Google Scholar 

  25. Alberts AS, Falkson G, Rapoport BL, Uys A . A phase II study of idarubicin and prednisone in multiple myeloma. Tumori 1990; 76: 465–466.

    Article  CAS  Google Scholar 

  26. Alberts DS, Balcerzak SP, Bonnet JD, Stephens RL . Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study. Cancer Treat Rep 1985; 69: 1321–1323.

    CAS  PubMed  Google Scholar 

  27. Case Jr DC, Ervin TJ, Gams R et al. Phase I–II study of epirubicin in multiple myeloma. Cancer Res 1988; 48: 6246–6248.

    PubMed  Google Scholar 

  28. Chisesi T, Capnist G, de Dominicis E, Dini E . A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma. Eur J Cancer Clin Oncol 1988; 24: 681–684.

    Article  CAS  Google Scholar 

  29. Sumpter K, Powles RL, Raje N et al. Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma. Leuk Lymphoma 1999; 35: 593–597.

    Article  CAS  Google Scholar 

  30. Rodjer S, Nilsson B, Westin J . Do anthracyclines have a role in the therapy of multiple myeloma? Hematol J 2000; 1: 422–426.

    Article  CAS  Google Scholar 

  31. Hendler M, Corrado C, Lastiri F et al. Randomized clinical trial comparing melphalan–methyl prednisolone (MP) versus melphalan–methylprednisolone–adriamycin (MPA) in newly diagnosed patients with multiple myeloma. A GATLA study. VII International Multile Myeloma Workshop 1999. Stockholm, 1999 (Abstr. P 50).

  32. Majolino I, Vignetti M, Meloni G et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica 1999; 84: 844–852.

    CAS  Google Scholar 

  33. Alexanian R, Weber D, Delasalle K et al. Value of intensive therapy supported by autologous stem cells (IT+ASCT) for primary resistant multiple myeloma. Blood 2002; 100 (Abstr. #672).

  34. Anagnostopoulos A, Aleman A, Williams P et al. Autologous stem cell transplantation (ASCT) after nonmyelosuppressive induction therapy with dexamethasone alone is safe and effective for newly diagnosed multiple myeloma (MM) pts who receive high dose chemotherapy (HDC). Blood 2001; 98 (Abstr. # 2858).

  35. Weber D, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19.

    Article  CAS  Google Scholar 

  36. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by Hematological Malignancies Fund, Mayo Clinic and CA62242 from the National Cancer Institute. Presented at the Annual meeting of the American Society of Hematology, Philadelphia, December 2002.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN, USA

    S Kumar, M Q Lacy, A Dispenzieri, S V Rajkumar, R Fonseca, T E Witzig, J A Lust, P R Greipp, R A Kyle, M R Litzow & M A Gertz

  2. Department of Biostatistics, Mayo Clinic and Foundation, Rochester, MN, USA

    S Geyer & C Allmer

Authors
  1. S Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Q Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S V Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Geyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Allmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T E Witzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J A Lust
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P R Greipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R A Kyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M R Litzow
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M A Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Gertz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, S., Lacy, M., Dispenzieri, A. et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 34, 485–490 (2004). https://doi.org/10.1038/sj.bmt.1704633

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704633

Keywords

This article is cited by

Search

Advanced search

Quick links